Edwards Lifesciences (EW), a leading innovator in the structural heart disease space, saw its stock surge 7.18% in after-hours trading on Tuesday, February 11th, following the company's impressive fourth-quarter results and upbeat guidance for the year ahead.

The medical device maker reported better-than-expected earnings for the fourth quarter of 2024, driven by strong demand for its transcatheter aortic valve replacement (TAVR) devices and other structural heart products. Adjusted earnings per share (EPS) came in at $0.59, surpassing analysts' estimates of $0.55.

Revenue for the quarter rose 9% year-over-year to $1.39 billion, outperforming the consensus estimate of $1.358 billion. The company's TAVR sales grew 6%, while its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment witnessed an impressive 88% surge in sales to $105 million.

Looking ahead, Edwards Lifesciences reiterated its full-year 2025 adjusted EPS guidance range of $2.40 to $2.50, reflecting its confidence in continued growth across its product portfolio. The company also expects to receive approval for its EARLY TAVR trial, which could potentially expand the use of its TAVR devices to asymptomatic severe aortic stenosis patients in the U.S. by mid-year.

Analysts and investors alike were encouraged by the company's strong performance and positive outlook, attributing the after-hours stock surge to the robust financial results and promising growth prospects in the structural heart disease market.